Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CCR1 | P32246 | 3/20 | 0.78 |
| ▸ | CCR5 | P51681 | 3/20 | 0.78 |
| ▸ | CCR8 | P51685 | 3/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | METAP1 | P53582 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211369 | 1.00 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL1456153 | 1.00 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4189211 | 0.97 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4174742 | 0.97 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4178522 | 0.97 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4181725 | 0.93 | KDM4E (0.86) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL3753259 | 0.91 | KDM4E (0.82) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL3755174 | 0.91 | KDM4E (0.82) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| Dipyridyl SCHEMBL3711450 | 0.88 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT | |
| Dipyridyl SCHEMBL29907716 | 0.88 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101177-A1 | pH AND LIGHT ACTIVATED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2016-04-14 | — | — | US | claimed |
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, THE (KR) | 2009-02-05 | — | — | US | claimed |
| WO-2007007943-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OF CANCER COMPRISING PYRIDYLPYRIDAZINE COMPOUNDS OR THEIR TRANSITION METAL COMPLEXES | THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) (KR) | 2007-01-18 | — | — | WO | claimed |
| US-20230279019-A1 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| US-11560384-B2 | Benzonorbornadiene derivatives and reactions thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210164005-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2021-06-03 | — | — | US | disclosed |
| US-10875840-B2 | Methods for inducing bioorthogonal reactivity | UNIVERSITY OF DELAWARE (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190300539-A1 | Benzonorbornadiene Derivatives and Reactions Thereof | UNIVERSITY OF UTAH | 2019-10-03 | — | — | US | disclosed |
| US-9731001-B2 | Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1) | UNIVERSITE LAVAL (CA) | 2017-08-15 | — | — | US | disclosed |
| US-9731001-B2 | Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1) | UNIVERSITE LAVAL (CA) | 2017-08-15 | — | — | US | disclosed |
| US-9731001-B2 | Three-dimensional cavities of dendritic cell immunoreceptor (DCIR), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (HIV-1) | UNIVERSITE LAVAL (CA) | 2017-08-15 | — | — | US | disclosed |
| US-5120843-A | Nervous system disorders | UPJOHN (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0487510-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5099019-A | Central nervous system steroid derivative drugs | UPJOHN COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| US-4996318-A | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke | THE UPJOHN COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0354920-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1990-02-21 | — | — | EP | disclosed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | disclosed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300539-A1 | Benzonorbornadiene Derivatives and Reactions Thereof | CBR3, CBR1, CNR1 | KDM4E 2364/4885NPC1 2898/4885RAB9A 740/4885 |
| US-20160101177-A1 | pH AND LIGHT ACTIVATED ANTI-CANCER DRUGS | CA2, CA6, NFATC1 | KDM4E 3373/4885NPC1 4495/4885RAB9A 326/4885 |
| US-20230279019-A1 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | CBR3, CBR1, CNR1 | KDM4E 2296/4885NPC1 3409/4885RAB9A 648/4885 |
| US-11560384-B2 | Benzonorbornadiene derivatives and reactions thereof | CBR3, CBR1, CNR1 | KDM4E 2364/4885NPC1 2898/4885RAB9A 740/4885 |
| US-10875840-B2 | Methods for inducing bioorthogonal reactivity | CBR1, CBR3, DUOX1 | KDM4E 3543/4885NPC1 4645/4885RAB9A 3957/4885 |
| US-20090036418-A1 | Pharmaceutical composition for treatment of cancer containing pyridylpyridazine or transition metal complex thereof as active ingredient | CA5A, PDCD11, PDCD1 | KDM4E 1038/4885NPC1 4803/4885RAB9A 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.